Searchable abstracts of presentations at key conferences in endocrinology

ea0070aep1002 | Hot topics (including COVID-19) | ECE2020

Intact endothelial epoxyeicosatrienoic acids pathway in primary aldosteronism – the route to new treatment strategies?

Fruehbuss Laura , Meng Yao , Sun Jing , Gonzalez Marques Jair , Koletzko Berthold , Mederos Y Schnitzler Michael , Gudermann Thomas , Beuschlein Felix , Ann Williams Tracy , Heinrich Daniel , Adolf Christian , Reincke Martin , Schneider Holger

Rationale: Endothelial dysfunction (ED) is a hallmark of primary aldosteronism and paves the way for subsequent atherosclerotic disease. Past research has confirmed that one factor involved in ED is disturbed nitric oxide (NO) signalling. Since defects in NO release alone cannot explain the whole effect, we set out to address the role of endothelial CYP-expoygenase products (epoxyeicosatrienoic acids, EETs) in aldosterone-mediated endothelial dysfunction.<p class="abstext"...

ea0022oc4.1 | Adrenals | ECE2010

Subtype differentiation in primary hyperaldosteronism: evaluation of alternative algorithms avoiding a controversial gold standard

Lang Katharina , Hahner Stefanie , Vonend O , Rump L C , Quninkler M , Diederich Sven , Maier Katharina , Beuschlein Felix , Bidlingmaier Martin , Endres S , Engelke C , Kickuth Ralph , Fassnacht Martin , Reincke Martin , Allolio Bruno

Context: Primary aldosteronism (PHA) is the most common cause of secondary hypertension. Distinguishing unilateral (UAH) from bilateral (BAH) and other causes of PHA is one of the greatest challenges in the diagnostic process. Adrenal venous sampling (AVS) is widely considered to be the gold standard for subtype differentiation.Methods: Technical and diagnostic outcome of AVS was analysed retrospectively in 59 patients with PHA who underwent AVS at the U...

ea0016p333 | Endocrine tumours | ECE2008

Deficits in the clinical management of patients with adrenocortical carcinoma in Germany

Johanssen Sarah , Koschker Ann-Cathrin , Hahner Stefanie , Quinkler Marcus , Saeger Wolfgang , Morcos Michael , Willenberg Holger , Langer Peter , Klose Silke , Reisch Nicole , Beuschlein Felix , Brauckhoff Michael , Fottner Christian , Wortmann Sebastian , Oelkers Wolfgang , Maeder Uwe , Fassnacht Martin , Allolio Bruno

Adrenocortical carcinoma (ACC) is a rare disease with poor prognosis. Accordingly, in many cases, the attending doctors have no previous experience with the disease. The aim of our study was to evaluate the quality of care in a large number of patients with ACC in Germany. Data from 263 adult patients of the German ACC registry were analyzed with regard to the following parameters: time to diagnosis, hormonal assessment, imaging, histopathological documentation, follow-up. The...

ea0081oc1.3 | Oral Communications 1: Diabetes, Obesity, Metabolism and Nutrition 1 | ECE2022

Canakinumabin patients with COVID-19 and type 2 diabetes (CanCovDia) – a multicentric, randomised, double-blind, placebo-controlled phase 3 trial

Hepprich Matthias , Mudry Jonathan , Gregoriano Claudia , Jornayvaz Francois R , Carballo Sebastian , Wojtusciszyn Anne , Bart Pierre-Alexandre , Chiche Jean-Daniel , Fischli Stefan , Baumgartner Thomas , Cavelti-Weder Claudia , Beuschlein Felix , Braun Dominque L , Gunthard Huldrych F , West Emily , Conen Anna , Isenring Egon , Bucklar Gabriela , Aubry Yoann , Dey Ludovic , Muller Beat , Schutz Philipp , Cattaneo Marco , Hunziker Patrick , Donath Marc Y

Background: Patients with type 2 diabetes and overweight have a chronic activation of the innate immune system possibly explaining the increased risk of a hyperinflammatory response and severe COVID-19. We aimed to test whether blockade of interleukin-1β(IL-1β) using canakinumab improves clinical outcome.Methods: CanCovDia was a multicenter, randomised, double-blind, placebo-controlled trial to assess the efficacy of canakinumab plus standard-o...

ea0081oc13.6 | Oral Communications 13: Adrenal and Cardiovascular Endocrinology 2 | ECE2022

Machine Learning models for the accurate prediction of malignant pheochromocytomas and paragangliomas

Pamporaki Christina , Berends Annika MA , Filippatos Angelos , Prodanov Tamara , Meuter Leah , Prejbisz Aleksander , Beuschlein Felix , Fassnacht Martin , Timmers Henri , Noelting Svenja , Abhyankar Kaushik Ganesh , Contsantinescu Georgiana , Kunath Carola , Wang Katharina , Remde Hanna , Januszewicz Andrzej , Robledo Mercedes , Lenders Jacques , Kerstens Michiel , Pacak Karel , Eisenhofer Graeme

Introduction: Pheochromocytomas and paragangliomas (PPGLs) exhibit an up to 20% malignancy rate. Various clinical, genetic, and pathological features have been proposed as predictors of malignancy. However, until present there are no robust indices to reliably predict metastatic PPGLs.Aim: The aim of the present study was to prospectively validate the value of methoxytyramine as risk marker of metastatic disease and establish a machine learning (ML) mode...

ea0050oc2.1 | Clinical Highlights | SFEBES2017

Mild autonomous cortisol excess in adrenal incidentalomas – metabolic disease burden and urinary steroid metabolome in 1201 prospectively recruited patients

Prete Alessandro , Taylor Angela E , Sitch Alice J , Gilligan Lorna C , Vassiliadi Dimitra , Ambroziak Urzula , Lang Katharina , Kastelan Darko , Tabarin Antoine , Dennedy M Conall , Ueland Grethe AEstrom , Quinkler Marcus , Masjkur Jimmy Rusdian , Fassnacht Martin , Ivovic Miomira , Terzolo Massimo , Beuschlein Felix , Manolopoulos Konstantinos , Tsagarakis Stylianos , Shackleton Cedric H L , Deeks Jonathan J , Bancos Irina , Arlt Wiebke

Background: Adrenal incidentalomas (AI) are found in approximately 5% of the adult population. Most AIs are benign; however, small-scale studies have indicated that 20–50% of patients harbouring a benign AI show biochemical evidence of mild autonomous cortisol excess (MACE), previously termed subclinical Cushing’s syndrome. MACE is differentiated into MACE-1 (serum cortisol after overnight suppression with 1 mg dexamethasone (1 mg-DST) 50–140 nmol/l) and MACE-2 ...

ea0050oc2.1 | Clinical Highlights | SFEBES2017

Mild autonomous cortisol excess in adrenal incidentalomas – metabolic disease burden and urinary steroid metabolome in 1201 prospectively recruited patients

Prete Alessandro , Taylor Angela E , Sitch Alice J , Gilligan Lorna C , Vassiliadi Dimitra , Ambroziak Urzula , Lang Katharina , Kastelan Darko , Tabarin Antoine , Dennedy M Conall , Ueland Grethe AEstrom , Quinkler Marcus , Masjkur Jimmy Rusdian , Fassnacht Martin , Ivovic Miomira , Terzolo Massimo , Beuschlein Felix , Manolopoulos Konstantinos , Tsagarakis Stylianos , Shackleton Cedric H L , Deeks Jonathan J , Bancos Irina , Arlt Wiebke

Background: Adrenal incidentalomas (AI) are found in approximately 5% of the adult population. Most AIs are benign; however, small-scale studies have indicated that 20–50% of patients harbouring a benign AI show biochemical evidence of mild autonomous cortisol excess (MACE), previously termed subclinical Cushing’s syndrome. MACE is differentiated into MACE-1 (serum cortisol after overnight suppression with 1 mg dexamethasone (1 mg-DST) 50–140 nmol/l) and MACE-2 ...

ea0065ec1.3 | Clinical Endocrinology Trust Best Abstract Clinical | SFEBES2019

Urine steroid metabolome analysis allows for metabolic risk stratification in 1309 prospectively recruited patients with benign adrenal tumours and different degrees of cortisol excess

Prete Alessandro , Taylor Angela E , Sitch Alice J , Gilligan Lorna C , Vassiliadi Dimitra , Ambroziak Urszula , Lang Katharina , Kastelan Darko , Tabarin Antoine , Dennedy M Conall , Ueland Grethe Astrom , Quinkler Marcus , Masjkur Jimmy Rusdian , Fassnacht Martin , Ivovic Miomira , Terzolo Massimo , Beuschlein Felix , Manolopoulos Konstantinos , O'Reilly Michael W , Tsagarakis Stylianos , Shackleton Cedric H L , Deeks Jonathan J , Bancos Irina , Arlt Wiebke

Background: Benign adrenal tumours (AT) can be non-functioning (NFAT) or associated with cortisol excess, as indicated by failure to suppress serum morning cortisol to <50 nmol/l in the 1mg-dexamethasone suppression test (1 mg-DST). The latter group divides into patients with clinically overt signs of cortisol excess (adrenal Cushing’s syndrome, CUSH) and patients lacking CUSH signs (mild autonomous cortisol excess, MACE). Smaller series and a recent meta-analysis rep...

ea0065op6.4 | Neuroendocrinology, Pituitary and Neoplasia | SFEBES2019

Urine steroid metabolomics as a novel diagnostic tool for recurrent adrenocortical carcinoma detection

Chortis Vasileios , Nijman Thomas , Bancos Irina , Gilligan Lorna C , Taylor Angela E , Ronchi Cristina L , O'Reilly Michael W , Schreiner Jochen , Asia Miriam , Riester Anna , Terzolo Massimo , Libe Rosella , Quinkler Marcus , Canu Letizia , Paiva Isabel , Bugalho Maria J , Kastelan Darko , Dennedy M Conall , Sherlock Mark , Ambroziak Urszula , Vassiliadi Dimitra , Bertherat Jerome , Beuschlein Felix , Fassnacht Martin , Deeks Jonathan J , Biehl Michael , Arlt Wiebke

Objective: Urine steroid metabolomics, combining mass spectrometry-based steroid profiling and machine learning, has been described as a novel diagnostic tool for detection of adrenocortical carcinoma (ACC). This proof-of-concept study evaluated the performance of urine steroid metabolomics as a tool for post-operative recurrence detection after microscopically complete (R0) resection of ACC.Methods: 135 ACC patients from 14 clinical centres provided pos...

ea0067o21 | Oral Presentations | EYES2019

Urine steroid metabolomics as a novel diagnostic tool for recurrent adrenocortical carcinoma detection

Chortis Vasileios , Bancos Irina , Nijman Thomas , Gilligan Lorna C , Taylor Angela E , Ronchi Cristina L , O'Reilly Michael W , Schreiner Jochen , Asia Miriam , Riester Anna , Terzolo Massimo , Libe Rosella , Quinkler Marcus , Canu Letizia , Paiva Isabel , Bugalho Maria J , Kastelan Darko , Dennedy M Conall , Sherlock Mark , Ambroziak Urszula , Vassiliadi Dimitra , Bertherat Jerome , Beuschlein Felix , Fassnacht Martin , Deeks Jonathan J , Biehl Michael , Arlt Wiebke

Objective: Urine steroid metabolomics, combining mass spectrometry-based steroid profiling and machine learning, has been described as a novel diagnostic tool for detection of adrenocortical carcinoma (ACC). This proof-of-concept study evaluated the performance of urine steroid metabolomics as a tool for post-operative recurrence detection after microscopically complete (R0) resection of ACC.Methods: 135 patients from 14 clinical centers provided post-op...